Ovarian cancer (OC) is the main cause of deaths worldwide in female reproductive system
malignancies. Growing studies have indicated that
eRNAs could regulate cellular activities in various
tumors. Yet the potential roles of
eRNAs in OC progression have not been elucidated. Thus, comprehensive assays were needed to screen the critical
eRNAs and to explore their possible function in OC. We used Kaplan-Meier methods to identify survival-associated
eRNAs in OC based on TCGA datasets. The levels of ZFHX4-AS1 were examined using TCGA datasets. Further exploration was carried out based on the following assays: clinical and survival assays, GO terms, and KEGG assays. TIMER was applied to delve into the relationships between ZFHX4-AS1 and
tumor immune infiltration. In this research, we observed 71 survival-related
eRNAs in OC patients. ZFHX4-AS1 was highly expressed in OC specimens and predicted a poor prognosis of OC patients. In addition, high ZFHX4-AS1 expression was positively related to the advanced stages of OC specimens. Multivariate assays revealed that ZFHX4-AS1 was an independent prognostic factor for overall survival of OC patients. KEGG analysis indicated that ZFHX4-AS1 may play a regulatory effect on
TGF-beta signaling, PI3K-Akt signaling, and
proteoglycans in
cancer. The pan-
cancer validation indicated that ZFHX4-AS1 was related to survival in eight
tumors, namely, UCEC, STAD, SARC, OV, ACC, KICH, KIRC, and BLCA. The expression of ZFHX4-AS1 was correlated with the levels of B cells, T cell CD8+, neutrophil, macrophage, and myeloid dendritic cells. Simultaneously, ZFHX4-AS1 may be a prognostic
biomarker and a distinctly
immunotherapy-related eRNA in OC.